TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT Docket No. (Under 37 CFR 1.97(b) or 1.97(c)) 143.006 In Re Application Of: Higazi, Abd. Al-Roof Serial No. Filing Date Examiner Group Art Unit 10/063,046 14 March 2002 **TBA** TBA Title: Peptige for ion of urokinase plasminogen activator and method of optimizing therapeutic efficacy Address to: **Assistant Commissioner for Patents** Washington, D.C. 20231 37 CFR 1.97(b) The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. 37 CFR-1.97(c) The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: ☐ the statement specified in 37 CFR 1.97(e); OR ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT Docket No.								
	Jnder 37 CFR 1.97(b) or 1.97	7(c)) COPY OF FIPER ORIGINALLY FILE	S 143.006					
In Re Application: Higazi, Abd. Al-Roof								
Serial No.	Filing Date	Examiner	Group Art Unit					
10/063,046	14 March 2002	ТВА	ТВА					
epide for egulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy								
STENT & TRANS	Payr	nent of Fee						
	(Only complete if Applicant ele	ects to pay the fee set forth in 37 CFR 1.	17(p))					
<ul> <li>□ A check in the amount of is attached.</li> <li>□ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. as described below. A duplicate copy of this sheet is enclosed.</li> <li>□ Charge the amount of</li> <li>□ Credit any overpayment.</li> <li>□ Charge any additional fee required.</li> </ul>								
Certificate of	Transmission by Facsimile*	Certificate of Mailing by	First Class Mail					
I certify that this docume account is being facsing Patent and Trademark (Date)	ent and authorization to charge deposit mile transmitted to the United States Office (F	certify that this document and 29 April 2002 with the asterior of the Assistant Communication (Control of the Assistant Communication) (Control of the Assistant Control of the Assist	he U.S. Postal Service C.F.R. 1.8 and is					
	Signature	Signature of Person Mai	ling Correspondence					
		Alicia Y. McGlynn						
Typed or Printed N	ame of Person Signing Certificate	Typed or Printed Name of Perso	n Mailing Certificate					
Kashide	y only be used if paying by  A Lamal  gnature	Dated: 4/29/02						
CC:								

`	INFO	DMATION DISCLOSID	E CITAZION	E ·/C	Docket Number (Optional) 143.00 Applicant(s)	6	Application Num
	пчго	RMATION DISCLOSUR (Use several sineets if necess	sary)	E CO	HIGAZI, Abd. Al-		Group Art Unit
					14 March	2002	
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	MADE	NAME	CLASS	SUBCLASS
	A	4,558,010	12/10/85	Hung e	t al.	435	212
					<del></del>	38	
					ORIGINALLY FIL	ED	
					···-		
			***	FOREIG	N PATENT DOCUMEN	TS	1
	REF	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS
			ļ				
· · · · - · · · - · · · · · · · · · · ·							
		Simmons M. Cardiol.	Clin 1995, 13:33		DOCUMENTS (Include	ling Author, Title,	Date, Pertinent
	٠	В	Ciii 1993, 13.33.	, 313			
		Cipolla M et al., Strok	e 2000, 31:940-9	45			
		С					
EXAMINE	CR				DATE CONSIDERED		
EXAMINE	R: Init	ial if citation considered, whethe	r or not citation is	in conforma	nce with MPEP Section 6	09; Draw line thro	ough citation if r

*				Docket Number (Optional)	Application Number			
INE	^DM	ATION DISCLOSURE CITA	DE JO	143.006 Applicant(s)	10/063,046			
HAL		(Use séveral sheets if necessary)	AND TO	HIGAZI, Abd. Al-Roof	Group Art Unit			
			MH 0 8 JULY E	iling Date 14 March 2002	Group Art Unit TBA			
*EXAMINER INITIAL		OTHER DOCUMENTS	Induding Author Vill	lle, Date, Pertinent Pages, Etc.)				
		Higazi, A. AR et al., The Jou	arnal of Biological Ch	hemistry, 1995, 270:9472-9477	F PAPERS			
•	D				rayens			
		Wardlaw, J.M. et al., Lancet, 1997, 350:607-614						
	E				I			
<del></del>								
		Erdem, Y. et al., American Jo	urnal of Hypertensio	n, Ltd., 1999, 11:1071-1076				
:	F				Ţ			
		The Io	1 -f Dialogical C	· · · · · · · · · · · · · · · · · · ·				
		Adams, David S. et al., The Jon	urnal of Biological Ci	Chemistry, 1991, 266:8476-8482				
	G							
		True Toochim et al. "I RP: 9		enger and signaling receptor", J. Clin.	T 2001 100:770 79/			
		Herz, Joachin et al., Line a	MUITHURCHORAL SCANC	inger and signature receptor , o. Can-	. Invest., 2001, 108:117-104			
	н							
		Hai-Vehia A. et al "Urokina	ase_derived pentides	regulate vascular smooth muscle conti	raction in vitro and in vivo". The			
		FASEB Journal, 2000, 14:1411	1-1422	regulate vascular smooth muscle contr	attivii iii viti v and in 1110, 200			
	I							
		Madison, E. L. et al., "Amino	acid residues that aff	fect interaction of tissue-type plasmino 37 (1990), 87:3530-3533	gen activator with plasminogen			
1		activator inhibitor 1", Proc. 14:	atl. Acad. Sci. USA 8	7 (1990), 87:3530-353 <i>5</i>				
	j	<u>-</u>						
		Madison, E. L. et al., "Restora Chemistry, 1990, 265:21423-21	ation of Serine Protea	ase-Inhibitor Interaction by Protein En	agineering", The Journal of Biological			
I	K	Chemistry, 1990, 200:21423-21	1426					
	_							
ļ								
!								
EXAMINER				DATE CONSIDERED				
2774 231-241			ļ					
+TV AMINED. I	-tetal if	Sale-tion considered whether or not	f -itatia- is in conforms	with MDED Section (00) Draw line th				
		e copy of this form with next commu		ance with MPEP Section 609; Draw line the	rough citation it not in conformance and			